Email Updates

You are here

Long-Acting Injectable Cabotegravir

Learn more about long-acting injectable PrEP—an experimental strategy based on the antiretroviral cabotegravir that’s shown high levels of protection in HPTN 083, a trial among men who have sex with men and transgender women, with more results on the way.

Scroll down for resources on CAB-LA research and advocacy.

Understanding the Research Results

Putting the Research in Context